Psychedelic use and psychiatric risks
- PMID: 37874345
- PMCID: PMC11039563
- DOI: 10.1007/s00213-023-06478-5
Psychedelic use and psychiatric risks
Abstract
Rationale: Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics.
Objective: The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks.
Methods: Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N=2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms.
Results: Among respondents who reported lifetime psychedelic use (n=613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders.
Conclusions: Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.
Keywords: HPPD; Psychedelics; Psychotic; Risks; Visual.
© 2023. The Author(s).
Conflict of interest statement
Declarations. Ethical approval: All procedures performed involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was deemed to be exempt by the Internal Review Board (IRB) at UW-Madison. Informed consent: Informed consent was obtained from all individual participants included in the studies. Conflict of interest: PSH has been in paid advisory relationships with the following organizations regarding the development of psychedelics and related compounds: Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, Journey Colab Corporation, Reset Pharmaceuticals Inc., and Silo Pharma. OS and RC were co-founders of Eudelics AB.
Similar articles
-
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.Psychol Med. 2025 Mar 31;55:e99. doi: 10.1017/S0033291725000716. Psychol Med. 2025. PMID: 40162511 Free PMC article.
-
Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.Psychedelic Med (New Rochelle). 2025 May 26;3(2):93-102. doi: 10.1089/psymed.2024.0036. eCollection 2025 Jun. Psychedelic Med (New Rochelle). 2025. PMID: 40530408
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Droperidol for psychosis-induced aggression or agitation.Cochrane Database Syst Rev. 2016 Dec 15;12(12):CD002830. doi: 10.1002/14651858.CD002830.pub3. Cochrane Database Syst Rev. 2016. PMID: 27976370 Free PMC article.
Cited by
-
Case Files of the Emory University Medical Toxicology Fellowship: A Patient Presents to the Outpatient Toxicology Clinic with Delusions of Being Poisoned.J Med Toxicol. 2024 Apr;20(2):233-244. doi: 10.1007/s13181-024-00995-1. Epub 2024 Feb 20. J Med Toxicol. 2024. PMID: 38378951 Free PMC article. No abstract available.
-
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.Psychol Med. 2025 Mar 31;55:e99. doi: 10.1017/S0033291725000716. Psychol Med. 2025. PMID: 40162511 Free PMC article.
-
Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders.Psychedelic Med (New Rochelle). 2025 May 26;3(2):93-102. doi: 10.1089/psymed.2024.0036. eCollection 2025 Jun. Psychedelic Med (New Rochelle). 2025. PMID: 40530408
-
Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.J Psychopharmacol. 2024 Jan;38(1):110-115. doi: 10.1177/02698811231218931. Epub 2023 Dec 23. J Psychopharmacol. 2024. PMID: 38140891 Free PMC article.
-
Examining the Gateway Hypothesis and Mapping Substance Use Pathways on Social Media: Machine Learning Approach.JMIR Form Res. 2024 May 7;8:e54433. doi: 10.2196/54433. JMIR Form Res. 2024. PMID: 38713904 Free PMC article.
References
-
- American Psychiatric Association (2013) Diagnostic and statistical manual of mental diseases (DSM-V), 5th edn. American Psychiatric Association Press, Washington, DC
-
- Andersen KA, Carhart-Harris R, Nutt DJ, Erritzoe D (2021) Therapeutic effects of classic serotonergic psychedelics: a systematic review of modern-era clinical studies. Acta Psychiatr Scand 143(2):101–118 - PubMed
-
- Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (2011) Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 114(1):61–67 - PubMed
-
- Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402–1411 - PubMed
-
- Faul F, Erdfelder E, Buchner A, Lang AG (2009) Statistical power analyses using G* Power 3.1: tests for correlation and regression analyses. Behav Res Methods 41(4):1149–1160 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous